Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials
Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced the publication of a peer-reviewed Viewpoint in the European Respiratory Journal (ERJ).
Read original article on The Medical News →Related news
-
Q&A: The science behind the fall time change
United Kingdom
-
Does choosing organic baby food change its mineral content?
United Kingdom
-
Sleep health expert explains how falling back affects the body clock
United Kingdom
-
Strangers Ran Towards the Fire to Save Teen–Her Mom Now Funds Scholarships for Heroes Like Them
United Kingdom
-
Swedish dietary surveys link higher ultraprocessed food intake to poorer nutrition
United Kingdom
-
Two economists studied California's billionaire tax. They reached wildly different conclusions
United States
-
Hypertension or diabetes before pregnancy linked to higher risk of fetal heart defects
United Kingdom
-
Cardiac arrest ICU admissions rose with outdoor heat, especially in women, older adults
United Kingdom